IDH2 and central nervous system cancer: It takes into account the N6-methyladenosine (m6A) modification landscapes of specific miRNAs in low-grade gliomas (LGGs; in particular, grades II and III) and appears to be more specific in discriminating between low- and high-risk gliomas than IDH status [68].